The Paracrine Function of Mesenchymal
Stem Cells in Response to Pulsed Focused Ultrasound

Mehdi Razavi1,2,3,*, Melika Rezaee1,*, Arsenii Telichko1, Hakan Inan1, Jeremy Dahl1, Utkan Demirci1, and Avnesh S. Thakor1

Abstract
We studied the paracrine function of mesenchymal stem cells (MSCs) derived from various sources in response to pulsed focused ultrasound (pFUS). Human adipose tissue (AD), bone marrow (BM), and umbilical cord (UC) derived MSCs were exposed to pFUS at two intensities: 0.45 W/cm² ISATA (310 kPa PNP) and 1.3 W/cm² ISATA (540 kPa PNP). Following pFUS, the viability and proliferation of MSCs were assessed using a hemocytometer and confocal microscopy, and their secreted cytokine profile determined using a multiplex ELISA. Our findings showed that pFUS can stimulate the production of immunomodulatory, anti-inflammatory, and angiogenic cytokines from MSCs which was dependent on both the source of MSC being studied and the acoustic intensity employed. These important findings set the foundation for additional mechanistic and validation studies using this novel noninvasive and clinically translatable technology for modulating MSC biology.

Keywords
mesenchymal stem cells, paracrine function, pulsed focused ultrasound

Introduction
Mesenchymal stem cells (MSCs) are multipotent stem cells¹ that can be isolated from various tissues²–¹⁰. Although bone marrow-derived MSCs (BM-MSCs) have traditionally been used as the main source of MSCs in clinical practice, MSCs derived from adipose tissue (AD-MSCs) and umbilical cord (UC-MSCs) have emerged as new and readily available sources with well-documented regenerative and immunomodulatory properties¹¹–¹⁴. While AD-MSCs can be easily isolated with high yield from adipose tissue obtained during routine liposuction/lipoplasty procedures¹⁵, UC-MSCs are retrieved from the umbilical cord which is considered a medical waste at the time of birth.

MSCs actively secrete cytokines and growth factors that act either on themselves (autocrine function) or neighboring cells (paracrine function) to modulate the immune system, inflammatory response, as well as stimulate neo-angiogenesis¹⁶. For instance, MSC-secreted cytokines have been implicated in the repair and regeneration of the central nervous system (CNS)¹⁷, heart¹⁸–²¹, bone¹⁶,²², and other damaged tissues²³. Given that MSCs have the ability to sense and respond to various stimuli²⁴–²⁶, several groups have investigated preconditioning MSCs (i.e., intentionally exposing them to a controlled amount of stimulus for a defined period of time in order to produce the desired response) to enhance their secretion of trophic factors¹⁶; these stimuli include hypoxia²⁷, thermal shock induction²⁸, pharmacologic treatment²⁹, and proinflammatory (i.e., interferon-gamma [IFN-γ] or tumor necrosis factor-alpha [TNF-α]) cytokine exposure³⁰,³¹. However, following their administration into patients, there is currently no way in which MSCs can be actively stimulated.

¹ Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, USA
² Bionix™ (Bionic Materials, Implants & Interfaces) Cluster, Department of Internal Medicine, College of Medicine, University of Central Florida, Orlando, FL, USA
³ Department of Materials Science and Engineering, University of Central Florida, Orlando, FL, USA
* Both the authors contributed equally to this article
Submitted: April 9, 2020. Revised: July 23, 2020. Accepted: September 21, 2020.

Corresponding Author:
Avnesh S. Thakor, Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, 3155 Porter Drive, Palo Alto, CA 94304, USA.
Email: asthakor@stanford.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
One approach to noninvasively stimulate MSCs, in a controlled and systematic way outside of the body, as well as inside the body following their administration, is to utilize sound waves. Focused ultrasound (FUS) is a novel technology, which can focus sound waves at specific locations deep in the body with pinpoint accuracy but without the use of any incisions. Pulsed FUS (pFUS) is a variation of this technology that uses short duty cycles to minimize temperature elevations, thereby allowing the biomechanical effects of ultrasound to predominate. We have recently shown that pFUS can stimulate pancreatic islets to increase insulin release. Hence, we hypothesized that pFUS can also stimulate MSCs and modulate their paracrine function by changing their profile of secreted cytokines. We therefore examined the effect of pFUS on the viability and function (determined by their paracrine function) of MSCs derived from various sources (i.e., BM, AD, and UC-MSCs).

Materials and Methods

MSC Isolation and In Vitro Expansion

Human AD-MSCs and UC-MSCs were kindly donated from the University of Miami (from Drs Ricordi and Patel) and human BM-MSCs were donated from the laboratory of diagnostic research at the NIH (from Dr Frank). All MSCs were fully characterized as previously described. BM-MSCs and AD-MSCs were cultured in Mesenchymal Stem Cell Growth Medium (Lonza, NJ, USA), supplemented with 10% fetal bovine serum (FBS) with additional supplements (MSCGM hMSC SingleQuot Kit, Lonza, NJ, USA). UC-MSCs were cultured in low glucose Dulbecco’s modified Eagle medium (Fisher Scientific, Grand Island, NY, USA) supplemented with 10% XcytepLUS (ibiologics), 1% glutamax (Gibco, Grand Island, NY, USA), 1% nonessential amino acid solution (NEAA; Gibco), and 1% penicillin and streptomycin (Life Technologies, Grand Island, NY, USA). All cells were cultured in the incubator at 37 °C with 5% carbon dioxide (CO2), and the culture media were changed every 3 days.

MSC Stimulation with pFUS

pFUS was performed on MSCs as described previously. For each pFUS treatment, experiments were performed using a six-well plate (Corning, USA) containing 10^5 MSCs/well. MSCs (BM-MSC, AD-MSC, and UC-MSC) were first cultured in well-plates for 24 h; the plates were then immersed in an autoclaved water bath and placed above the pFUS transducer (KB Aerotech Inc., Lewiston, PA, USA) at the transducer’s focal spot (i.e., 50 mm away from the transducer surface). For sound waves to cover all of MSCs cultured in each well-plate, each well was divided into 25 spots (5 x 5 mesh, 5.75 mm distance between each point). Culture plates were immobilized, while a 1 MHz piston transducer was attached to an Acoustic Intensity Measurement System (AIMS III, Onda, Sunnyvale, CA, USA) for precise positioning of the pFUS transducer to cover all 25 spots. The following pFUS parameters were fixed: 1 MHz frequency, 20% duty cycle, 100 Hz pulse repetition frequency, with a total duration time of 6 min (i.e., 14.4 s/spot). MSCs were then divided into three groups: Group 1: MSCs stimulated with low intensity pFUS (i.e., 0.45 W/cm^2 I_{SATA}; 310 kPa peak negative pressure [PNP]); Group 2: MSCs stimulated with high intensity pFUS (i.e., 1.3 W/cm^2 I_{SATA}; 540 kPa PNP); and Group 3: MSCs with no pFUS stimulation (controls). Each treatment was repeated in duplicate.

Analysis of MSC-Secreted Cytokines

Following pFUS stimulation, MSCs were incubated at 37 °C and 5% CO2 for 48 h, after which time their culture media was collected for multiplex immunoassay analysis (human multiplex ELISA; eBiosciences/Affymetrix/Fisher) to assess and measure the levels of secreted cytokines. In brief, beads were first added to a 96-well plate and washed (Biotek EL ×405). Samples were then added to the plate containing the mixed antibody-linked beads and incubated at room temperature for 1 h followed by overnight incubation at 4 °C on a plate shaker (500 rpm). A biotinylated detection antibody was then added, after which the plates were incubated at room temperature for 75 min on a plate shaker (500 rpm). Next, the samples were washed and streptavidin-phycoerythrin added followed by incubation of the plates for 30 min at room temperature on a plate shaker (500 rpm). The plates were then washed, and a reading buffer was added to the wells. Finally, a Luminex Flex 3D instrument was used to read the plates with a lower bound of 50 beads per sample per cytokine. Control assay beads (Radix Biosolutions) were added to wells. Multiplex ELISA assays were performed on all three sources of MSCs (i.e., BM-MSC, AD-MSC, and UC-MSC), which were sampled twice, and the average cytokine value was taken from two separate readings. The percentage change in cytokine expression from pFUS-stimulated MSCs relative to control (i.e., nonstimulated) MSCs was then calculated (Eq. 1):

\[
\text{Percentage change vs. control} = \frac{\text{OD}_{\text{sample}} - \text{OD}_{\text{control}}}{\text{OD}_{\text{control}}} \times 100
\]

where OD_{sample} is the optical density (absorbance) of MSCs stimulated with pFUS and OD_{control} is the optical density of control MSCs. Data were compiled as a heat map with upregulation represented as a red color gradient and downregulation represented as a green color gradient. We then categorized secreted cytokines into three subgroups: immunomodulatory, anti-inflammatory, and angiogenic cytokines.

Determination of MSCs’ Morphology and Viability

Following pFUS stimulation, MSCs were incubated at 37 °C and 5% CO2 for 48 h and then harvested and counted using a hemocytometer. Cell numbers were compared with the cell
number at time point 0, and the results expressed as the fold change versus control. Cell morphology was also observed under a confocal microscope (Zeiss LSM710).

**Statistical Analysis**

All experimental data are expressed as the mean ± SEM. Statistical analysis of all quantitative data was performed using one-way analysis of variance with post hoc Tukey test (Astatas.com; Online Web Statistical Calculators, USA) with any differences considered statistically significant when \( P < 0.05 \).

**Results**

**Analysis of MSC-Secreted Cytokines**

**BM-MSCs.** Stimulation of BM-MSCs with low-intensity and high-intensity pFUS resulted in a 15% ± 20% and 5% ± 10% increase in cytokine secretion, respectively, when compared with control BM-MSCs (Fig. 1A, \( P < 0.05 \)). Stimulation of BM-MSCs with low-intensity pFUS upregulated the expression of a subset of immunomodulatory (IL31, SCF, RANTES, IFNG, MIP1B, IFNA, TNFB, GROA, IL1A, IL12P40, IL15, IL18, MCP3, ICAM1, VCAM1, IL22, and ENA78), anti-inflammatory (FASL, IL1B, TGBF, IL1RA, TGBF, IL9, BDNF, TRAIL, IL10, and IFNB), and angiogenic (VEGFG, VEGF, FGB, IL2, and EOTAXIN) cytokines, while also downregulating the expression of a subset of immunomodulatory (IL15, MCP3, ICAM1, VCAM1, LEPTIN, and IL17F), anti-inflammatory (MIP1A, IL6, IL8, LIF, IFNB), and angiogenic (HGF, VEGFG, PDGFBB, VEGF, TGFA, IL7, IL2, EOTAXIN) cytokines when compared with control BM-MSCs (Fig. 1B, \( P < 0.05 \)).

**AD-MSCs.** Stimulation of AD-MSCs with low-intensity and high-intensity pFUS resulted in a 3% ± 5% and 5% ± 7% increase in cytokine secretion, respectively, when compared with control AD-MSCs (Fig. 1A, \( P < 0.05 \)). Stimulation of AD-MSCs with low-intensity pFUS upregulated the expression of a subset of immunomodulatory (IL15, MCP3, VCAM1, and IL17F), anti-inflammatory (MIP1A, IL1B, and IFNB), and angiogenic (VEGFG, VEGF, TGFA, FGB, and PAI1) cytokines, while also downregulating select immunomodulatory (IL23), anti-inflammatory cytokine (TGBF) and angiogenic (IL2, and IP10) cytokines when compared with control BM-MSCs (Fig. 1B, \( P < 0.05 \)).

**UC-MSCs.** Stimulation of UC-MSCs with low-intensity and high-intensity pFUS resulted in a 10% ± 15% and 15% ± 17% increase in the cytokine secretion, respectively, when compared with control UC-MSCs (Fig. 1A, \( P < 0.05 \)). Stimulation of UC-MSCs with low-intensity pFUS upregulated the expression of a subset of immunomodulatory (GMCSF, TNFA, MCP1, IL12P40, RESISTIN, VCAM1, LEPTIN, CD40 L, IL17F), anti-inflammatory (MIP1A, IL6, IL8, LIF, IFNB), and angiogenic (HGF, VEGFG, PDGFBB, VEGF, TGFA, IL7, IL2, EOTAXIN) cytokines, while also downregulating the expression of immunomodulatory (IL31, MIP1B, TNFB, IL1A, IL23, IL15, IL18), anti-inflammatory (FASL, IL1B, IL1RA, BDNF, TRAIL), and the angiogenic cytokine IP10 when compared with control UC-MSCs (Fig. 1B, \( P < 0.05 \)). Stimulation of UC-MSCs with high-dose pFUS caused upregulation of a subset of immunomodulatory (SCF, RANTES, TNFA, MCP1, GROA, IL1A, IL12P40, IL18, MCP3, MIG, RESISTIN, IL21, ICAM1, VCAM1, LEPTIN, CD40 L, EN78, and IL17F), anti-inflammatory (MIP1A, IL6, IL8, LIF, NGF, EGF, GCSF, CD40 L, IL17F), and angiogenic (HGF, VEGFG, PDGFBB, TGFA, SDF1A, IL5, IL7, IL2, and EOTAXIN) cytokines. High-dose pFUS also caused downregulation of the immunomodulatory cytokine IL15 when compared with control UC-MSCs (Fig. 1B, \( P < 0.05 \)).

**Determination of MSCs’ Morphology and Viability**

Stimulation of all three types of MSCs (i.e., BM-MSCs, AD-MSCs, and UC-MSCs) with pFUS, at both low and high intensities, did not significantly change the morphology and viability of MSCs compared to their control (Fig. 2; BM-MSCs: low intensity = 1.01 ± 1.00 fold change vs control, high intensity = 1.02 ± 1.05, control = 1.00 ± 0.50; AD-MSCs: low intensity = 0.85 ± 1.13, high intensity = 0.90 ± 0.77, control = 1.00 ± 0.50; UC-MSCs: low intensity = 0.96 ± 0.60, high intensity = 0.91 ± 1.02, control = 1.00 ± 0.50; \( P > 0.05 \)).

**Discussion**

MSCs are a promising regenerative cellular therapy which have been shown to have a significant benefit in multiple preclinical models. In addition to BM-MSCs, AD-MSCs and UC-MSCs are now being used in clinical trials to treat multiple conditions. In this study, we investigated (1) whether pFUS (i.e., sound waves) can safely be used to biomechanically stimulate MSCs and if this is dependent on the acoustic intensity employed and (2) whether different sources of MSCs respond differently to pFUS, as determined by their cytokine profile.

Our results show that pFUS can be used in vitro, at low and high intensities, with no adverse effect on MSC morphology or viability. The effect of acoustic intensity on cytokines is dependent on the source of MSCs with BM-MSCs showing increased secretion at lower intensities, UC-MSCs...
showing increased secretion at higher intensities, and AD-MSCs demonstrating the least amount of sensitivity to sound waves at both high and low intensities. Finally, our results show MSCs respond to pFUS in a source-dependent manner, with each source producing a distinct cytokine profile (i.e., the highest level of a cytokine produced by BM-MSCs was IL15, for AD-MSCs was TGF-α, and for UC-MSCs was LIF).

Given that pFUS can produce a different profile of cytokines depending on the source of MSC, this will become important for choosing a specific MSC for a particular disease indication, especially if pFUS is used for preconditioning...
MSCs. In terms of the cytokine produced at the highest level for each MSC, IL15 has been shown to induce the differentiation and proliferation of T, B, and natural killer cells and induces maturation of dendritic cells, thereby highlighting an important immunomodulatory function. TGF-α has been shown to initiate multiple cell proliferation events that play a role in wound healing as well as promoting angiogenesis. LIF has been shown to promote growth and cell differentiation as well as modulate embryonic stem cell self-renewal and differentiation.

Taken together, it is clear that pFUS can be used to stimulate MSCs. While the present study did not investigate the mechanisms underlying this effect, possible pathways include the mitogen-activated protein kinase, focal adhesion kinase activates-extracellular signal-regulated kinase 1/2, and stromal cell-derived factor-1/C-X-C chemokine receptor type 4. These pathways have already been shown to be activated following stimulation of stem cells with low-intensity pulsed ultrasound (LIPUS). Future work will aim to investigate these mechanisms systemically.
and the effects of different acoustic parameters on these pathways, in order to better determine how to effectively modulate the function of MSCs. Similar to other studies that have compared the secretory profile of MSCs in response to proinflammatory cytokines, our data also show that different sources of MSCs respond differently to the same stimulus (i.e., sound waves)\textsuperscript{50,51}. Future studies will aim to better understand the underlying molecular biology governing these changes as well as other regenerative outputs of MSCs (i.e., contents of their extracellular vesicles).

Ultrasound also has a well-documented influence on MSC differentiation. However, there are some inconsistencies, regarding how it affects MSCs in normal culture conditions. While Kusuyama et al found that LIPUS enhances stemness, in part by upregulating the stem cell factor Nanog\textsuperscript{52}, Lai et al found that LIPUS pushes MSCs toward an osteogenic fate\textsuperscript{53}, whereas Lee et al found continuous LIPUS (cLIPUS) to push MSCs to a chondrogenic fate\textsuperscript{54}. These discrepancies may arise due to different ultrasound settings, culture conditions, or cell source. What has consistently been demonstrated is that when MSCs are already induced toward a certain fate, LIPUS differentiates differentiation toward that lineage. For MSCs cultured in osteogenic induction media, LIPUS enhances the expression of osteogenic markers\textsuperscript{55}. When MSCs are cultured in a chondrogenic medium, cLIPUS and LIPUS enhance the expression of chondrogenic genes and the production of glycosaminoglycans\textsuperscript{56}. Finally, a few studies have shown that cLIPUS\textsuperscript{57} and LIPUS\textsuperscript{58} enhance the differentiation of MSCs into neural fates, increasing the secretion of neurotrophic factors as well as the expression of neural markers and calcium channels\textsuperscript{57}. While changes in the MSC secretome were evaluated in our study, the phenotype stability of MSCs was not investigated. However, previous studies\textsuperscript{59–61} have shown that the MSC phenotype is a function of ultrasound intensity. For example, a low-intensity ultrasound (<0.2 W/cm\textsuperscript{2}), applied as pulsed LIPUS or cLIPUS wave, has been documented to enhance the chondrocyte phenotype\textsuperscript{59}, improve cartilage repair\textsuperscript{60}, and induce hBM-MSC chondrogenesis \textit{in vitro}\textsuperscript{61} and \textit{in vivo}\textsuperscript{62}, notably in the absence of exogenous chondroinductive biochemical factors\textsuperscript{54}. There is therefore a possibility of changes in phenotype and differentiation potential in MSCs using our pFUS parameters in both low (0.45 W/cm\textsuperscript{2}) and high (1.3 W/cm\textsuperscript{2}) intensities; however, further studies will be required to evaluate this phenomenon.

Finally, we will aim to better understand the ability of translating this approach of using pFUS from the \textit{in vitro} setting (to precondition MSCs) to \textit{in vivo} setting where we can stimulate MSCs after they have been given into living subjects. Once the pFUS parameters are optimized and validated, clinical applications of pFUS will only require that the derated pFUS parameters match the optimized determined pFUS parameters.

In summary, our study showed that pFUS can stimulate MSCs, and the response profile is dependent on the intensity of pFUS as well as the source of MSC. These important findings should set the foundation for additional mechanistic and validation studies using this noninvasive and translatable technology in regenerative medicine.

**Ethical Approval**

Stanford University does not require ethical approval for the use of MSCs in research.

**Statement of Human and Animal Rights**

Based on Stanford’s IRB, the research using MSCs does not involve human subjects as defined in 45 CFR 46.102(f) or 21 CFR 50.3(g).

**Statement of Informed Consent**

There are no human subjects in this article and informed consent is not applicable.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the NIDDK (R01DK119293) and the Akiko Yamazaki and Jerry Yang Faculty Scholar Fund in Pediatric Translational Medicine and the Stanford Maternal and Child Health Research Institute.

**ORCID iD**

Avnesh S. Thakor  
https://orcid.org/0000-0001-7395-0515

**References**

1. Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195.
2. Gncechi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. In Stem Cells in Regenerative Medicine. Springer; 2009. pp. 281–294.
3. Gruber HE, Deepe R, Hoelscher GL, Ingram JA, Norton HJ, Scannell B, Loeffler BJ, Zinchenko N, Hanley EN, Tapp H. Human adipose-derived mesenchymal stem cells: direction: to a phenotype sharing similarities with the disc, gene expression profiling, and coculture with human annulus cells. Tissue Eng Part A. 2010;16(9):2843–2860.
4. Ishige I, Nagamura-Inoue T, Honda MJ, Harnprasopwat R, Kido M, Sugimoto M, Nakauchi H, Tojo A. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord. Int J Hematol. 2009;90(2):261–269.
5. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, Mortier C, Bron D, Lagneaux L. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells. 2005;23(8):1105–1112.
6. Bieback K, Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther. 2007;2(4):310–323.
7. Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004;22(7):1338–1345.
8. Ponnaiyan D, Bhat K, Bhat G. Comparison of immunophenotypes of stem cells from human dental pulp and periodontal ligament. Int J Immunopathol Pharmacol. 2012;25(1):127–134.
9. Joshi M, Patil PB, He Z, Holgersson J, Olausson M, Sumitran-Holgersson S. Fetal liver-derived mesenchymal stromal cells augment engraftment of transplanted hepatocytes. Cytotherapy. 2012;14(6):657–669.
10. Noort W, Scherjon S, Kleijburg-van der Keur C, Kruisbeek A, Van Bezooyen R, Beehuizen W, Willemze R, Kanhai H, Fibbe W. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. 2003;88(8):845–852.
11. Sun Z, Wang S, Zhao RC. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 2014;7:14.
12. Kono TM, Sims EK, Moss DR, Yamamoto W, Ahn G, Diamond J, Tong X, Day KH, Territo PR, Hanenberg H, Traktuev DO, et al. Human adipose-derived stem/stromal cells protect against STZ-induced hyperglycemia: analysis of hASC-derived paracrine effectors. Stem Cells. 2014;32(7):1831–1842.
13. Dave SD, Vanikar AV, Trivedi HL. Extrinsic factors promoting in vitro differentiation of insulin-secreting cells from human adipose tissue-derived mesenchymal stem cells. Appl Biochem Biotechnol. 2013;170(4):962–971.
14. Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzuza E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, et al. Safety and efficacy of the in vitro expansion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD Trial [Randomized Clinical Trial of Intraumbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121(10):1192–1204.
15. Via AG, Frizziello A, Oliva F. Biological properties of mesenchymal stem cells from different sources. Muscles Ligaments Tendons J. 2012;2(3):154.
16. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regenerat Med. 2010;5(1):121–143.
17. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neurotogenesis. Exp Neurol. 2006;198(1):54–64.
18. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol. 2006;291(2):H886–H893.
19. Xu M, Uemura R, Dai Y, Wang Y, Pasha Z, Ashraf M. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol. 2007;42(2):441–448.
20. Kubal C, Sheth K, Nadal-Ginard B, Galíñanes M. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. J Thorac Cardiovasc Surg. 2006;132(5):1112–1118.
21. Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, Fischer P, Meyer GP, Ganser A, Drexler H, Wollert KC. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J. 2008;29(23):2851–2858.
22. Lin W, Xu L, Zwingenberger S, Gibon E, Goodman SB, Li G. Mesenchymal stem cells homing to improve bone healing. J Orthop Translat. 2017;9:19–27.
23. Fu X, Li H. Mesenchymal stem cells and skin wound repair and regeneration: possibilities and questions. Cell Tissue Res. 2009;335(2):317–321.
24. Arnsdorf EJ, Tummlap K, Kwon Ry, Jacobs CR. Mechanically induced osteogenic differentiation—the role of RhoA, ROCKII and cytoskeletal dynamics. J Cell Sci. 2009;122(PT 4):546–553.
25. Li YJ, Batra NN, You L, Meier SC, Coe IA, Yellowley CE, Jacobs CR. Oscillatory fluid flow affects human marrow stromal cell proliferation and differentiation. J Orthop Res. 2004;22(6):1283–1289.
26. Kasper G, Gläser JD, Geissler S, Ode A, Tuischer J, Matziolos G, Perka C, Duda GN. Matrix metalloproteinase activity is an essential link between mechanical stimulus and mesenchymal stem cell behavior. Stem Cells. 2007;25(8):1985–1994.
27. Sharp FR, Ran R, Lu A, Tang Y, Strauss KI, Glass T, Ardizzzone T, Bernaudin M. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx. 2004;1(1):26–35.
28. Creagh E, Sheehan D, Cotter T. Heat shock proteins—modulators of apoptosis in tumour cells. Leukemia. 2000;14(7):1161.
29. Niagara MI, Haider HK, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res. 2007;100(4):545–555.
30. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2(2):141–150.
31. Yang C, Chen Y, Li F, You M, Zhong L, Li W, Zhang B, Chen Q. The biological changes of umbilical cord mesenchymal stem cells in inflammatory environment induced by different cytokines. Mol Cell Biochem. 2018;446(1–2):171–184.
32. Liu DD, Ullah M, Concepcion W, Dahl JJ, Thakor AS. The role of ultrasound in enhancing mesenchymal stromal cell-based therapies. Stem Cells Transl Med. 2020;9(8):850–866.
33. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliver Rev. 2008;60(10):1193–1208.
34. Razavi M, Zheng F, Telichko A, Wang J, Ren G, Dahl J, Thakor AS. Improving the function and engraftment of
transplanted pancreatic islets using pulsed focused ultrasound therapy. Sci Rep. 2019;9(1):13416. doi:10.1038/s41598-019-49933-0.

35. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabet Care. 2016;39(1):149–157.

36. Tremolada C, Palmieri G, Ricordi C. Adipocyte transplantation and stem cells: plastic surgery meets regenerative medicine. Cell Transplant. 2010;19(10):1217–1223.

37. Ziadloo A, Burks SR, Gold EM, Lewis BK, Chaudhry A, Merino MJ, Frenkel V, Frank JA. Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. Stem Cells. 2012;30(6):1216–1227.

38. Pelekanos RA, Sardesai VS, Futrega K, Lott WB, Kuhn M, Doran MR. Isolation and expansion of mesenchymal stem/stromal cells derived from human placenta tissue. J Vis Exp. 2016;(112):54204.

39. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829–849.

40. Couto PS, Shatirishvili G, Bersenev A, Verter F. First decade of clinical trials and published studies with mesenchymal stromal cells from umbilical cord tissue. Regen Med. 2019;14(4):309–319.

41. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19–49.

42. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14–32.

43. Schultz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem. 1991;45(4):346–352.

44. Buecker C, Chen HH, Polo JM, Daheron L, Bu L, Barakat TS, Okwia P, Porter A, Grünbau J, Hochedlinger K, Geijsen N. A murine ESC-like state facilitates transgenensis and homologous recombination in human pluripotent stem cells. Cell Stem Cell. 2010;6(6):535–546.

45. Chan YS, Göke J, Ng JH, Lu X, Gonzales KA, Tan CP, Tng H, Lim YS, Ng HH. Induction of a human pluripotent state with distinct regulatory circuitry that resembles preimplantation epiblast. Cell Stem Cell. 2013;13(6):663–675.

46. Gafni O, Weinberger L, Mansour AA, Manor YS, Chomskey E, Ben-Yosef D, Kalma Y, Viukov S, Maza I, Zviran A, Rais Y, et al. Derivation of novel human ground state naive pluripotent stem cells. Nature. 2013;504(7479):282–286.

47. Gao Q, Walmsley AD, Cooper PR, Scheven BA. Ultrasound stimulation of different dental stem cell populations: role of mitogen-activated protein kinase signaling. J Endod. 2016;42(3):425–431.

48. Chen J, Jiang J, Wang W, Qin J, Chen J, Chen W, Wang Y. Low intensity pulsed ultrasound promotes the migration of bone marrow-derived mesenchymal stem cells via activating FAK-ERK1/2 signalling pathway. Artif Cells Nanomed Biotechnol. 2019;47(1):3463–3613.

49. Wei F-Y, Leung K-S, Li G, Qin J, Chow SK-H, Huang S, Sun M-H, Qin L, Cheung W-H. Low intensity pulsed ultrasound enhanced mesenchymal stem cell recruitment through stromal derived factor-1 signaling in fracture healing. PLoS One. 2014;9(9):e106722.

50. Mizukami A, Caliari-Oliveira C, Cominal JG, Rocha JLM, Covas DT, Swiech K, Malmegrim KC. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10(1):131.

51. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandand AB. Pro-inflammatory cytokines, IFN-γ and TNF-α, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One. 2010;5(2):e9016.

52. Kusuyama J, Seong CH, Ohnishi T, Bandow K, Matsuguchi T. Low-intensity pulsed ultrasound (LIPUS) stimulation helps to maintain the differentiation potency of mesenchymal stem cells by induction in Nanog protein transcript levels and phosphorylation. J Orthop Trauma. 2016;30(8):S4–S5.

53. Lai C-H, Chen S-C, Chiu L-H, Yang C-B, Tsai Y-H, Zuo CS, Chang WH-S, Lai W-F. Effects of low-intensity pulsed ultrasound, dexamethasone/TGF-β1 and/or BMP-2 on the transcriptional expression of genes in human mesenchymal stem cells: chondrogenic vs. osteogenic differentiation. Ultrasound Med Biol. 2010;36(6):1022–1033.

54. Lee HJ, Choi BH, Min BH, Son YS, Park SR. Low-intensity ultrasound stimulation enhances chondrogenic differentiation in alginate culture of mesenchymal stem cells. Artif Organs. 2006;30(9):707–715.

55. Lim K, Kim J, Seonwoo H, Park SH, Choung P-H, Chung JH. In vitro effects of low-intensity pulsed ultrasound stimulation on the osteogenic differentiation of human alveolar bone-derived mesenchymal stem cells for tooth tissue engineering. BioMed Res Int. 2013;2013:269724.

56. Cui JH, Park SR, Park K, Choi BH, Min B-H. Preconditioning of mesenchymal stem cells with low-intensity ultrasound for cartilage formation in vivo. Tissue Eng. 2007;13(2):351–360.

57. Cho S-E, Kim Y-M, Jeong J-S, Seo Y-K. The effect of ultrasound for increasing neural differentiation in hBM-MSCs and inducing neurogenesis in ischemic stroke model. Life Sci. 2016;165:35–42.

58. Ning GZ, Song WY, Xu H, Zhu RS, Wu QL, Wu Y, Zhu SB, Li YC. The effect of low-intensity pulsed ultrasound on insulin secretion. Diabet Care. 2016;39(1):149–157.

59. Nishida T, Kubota S, Aoyama E, Yamanaka N, Lyons K, Takigawa M. Low-intensity pulsed ultrasound (LIPUS) treatment of cultured chondrocytes stimulates production of CCN family protein 2 (CCN2), a protein involved in the regeneration of articular cartilage: mechanism underlying
this stimulation. Osteoarthritis Cartilage. 2017;25(5): 759–769.
60. Cook SD, Salkeld SL, Patron LP, Doughty ES, Jones DG. The effect of low-intensity pulsed ultrasound on autologous osteochondral plugs in a canine model. Am J Sports Med. 2008; 36(9):1733–1741.
61. Schumann D, Kujat R, Zellner J, Angele M, Nerlich M, Mayr E, Angele P. Treatment of human mesenchymal stem cells with pulsed low intensity ultrasound enhances the chondrogenic phenotype in vitro. Biorheology. 2006; 43(3,4):431–443.
62. Yamaguchi S, Aoyama T, Ito A, Nagai M, Iijima H, Tajino J, Zhang X, Wataru K, Kuroki H. Effect of low-intensity pulsed ultrasound after mesenchymal stromal cell injection to treat osteochondral defects: an in vivo study. Ultrasound Med Biol. 2016;42(12):2903–2913.